clinical trial · NCT06388889
Phase III Long-Term Extension Study With Dexpramipexole
Areteia Therapeutics·phase3·terminated·n = 509
Eosinophilic AsthmaDexpramipexole Dihydrochloride
brief summary
The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 \[GINA, 2021\] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.
started
Jun 12, 2024
primary completion
Dec 8, 2025
completion
Dec 8, 2025
last updated
Dec 15, 2025
official title
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants With Severe Eosinophilic Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol